Keyphrases
Carvedilol
100%
Patients with Chronic Heart Failure
100%
Hospitalization Risk
42%
Placebo
28%
Beta-blockers
28%
Diuretics
28%
Risk of Death
28%
Percentage Reduction
28%
Digoxin
28%
Angiotensin-converting Enzyme Inhibitor (ACEi)
28%
Placebo Groups
28%
Placebo-controlled
14%
Chronic Heart Failure
14%
Safety Monitoring
14%
Treatment Protocol
14%
Patients with Heart Failure
14%
Mortality Rate
14%
Hospitalization
14%
Exercise Capacity
14%
Background Therapy
14%
Confidence Interval
14%
Worsening Heart Failure
14%
Left Ventricular Ejection Fraction
14%
Controlled Experiment
14%
Severe Heart Failure
14%
Adverse Reactions
14%
Mild Heart Failure
14%
Overall Mortality
14%
Hemodynamic Improvement
14%
Symptomatic Improvement
14%
Data Monitoring
14%
Monitoring Boards
14%
Combined Risk
14%
Medicine and Dentistry
Carvedilol
100%
Congestive Heart Failure
100%
Placebo
71%
Cardiovascular System
42%
Diuretic Agent
28%
ACE Inhibitor
28%
Beta Adrenergic Receptor Blocking Agent
28%
Digoxin
28%
Hemodynamic
14%
Adverse Event
14%
Mortality Rate
14%
Controlled Clinical Trial
14%
Heart Left Ventricle Ejection Fraction
14%
Attributable Risk
14%
Exercise
14%
Tilisolol
14%
Nursing and Health Professions
Congestive Heart Failure
100%
Carvedilol
100%
Placebo
71%
Dipeptidyl Carboxypeptidase Inhibitor
28%
Beta Adrenergic Receptor Blocking Agent
28%
Diuretic Agent
28%
Digoxin
28%
Mortality Rate
14%
Confidence Interval
14%
Heart Left Ventricle Ejection Fraction
14%
Adverse Event
14%
Attributable Risk
14%
Tilisolol
14%
Pharmacology, Toxicology and Pharmaceutical Science
Carvedilol
100%
Congestive Heart Failure
100%
Placebo
71%
Beta Adrenergic Receptor Blocking Agent
28%
Dipeptidyl Carboxypeptidase Inhibitor
28%
Diuretic Agent
28%
Digoxin
28%
Controlled Clinical Trial
14%
Adverse Event
14%
Mortality Rate
14%
Tilisolol
14%
Veterinary Science and Veterinary Medicine
Carvedilol
100%
Beta Blocker
28%
ACE Inhibitor
28%
Diuretic
28%
Hemodynamic
14%
Ejection Fraction
14%